Thalassaemia major (TM) is an inherited disease characterized by chronic haemolysis and ineffective erythropoiesis, requiring regular blood transfusions (Weatherall & Clegg, 1996) . Transfusions are lifesaving but, because the body does not have a mechanism to dispose of the excess iron (Hentze et al, 2004) , they can result in the accumulation of iron in different organs including the heart, liver and endocrine glands.
In the last 15 years the survival curve of TM patients has significantly changed (Telfer et al, 2006; Modell et al, 2008) and two factors contributed in parallel to the improvement in mortality. One driver was the introduction of oral iron chelators (Deferiprone and Deferasirox) (Pepe et al, 2006a) , next to the traditional subcutaneous Desferrioxamine. The second driver was the introduction in 1999 of the T2* cardiovascular magnetic resonance (CMR) technique for non-invasive and reliable assessment of myocardial iron overload (MIO) (Anderson et al, 2001 ). This technique had profound implications for the clinical management of TM patients, when used in the design of tailor-made chelation therapies customized for each patient, and in the evaluation of their efficacy (Pennell et al, 2010; Pepe et al, 2013) . Moreover, thank to its multiparametric potential, CMR enables heart function parameters to be quantified with excellent reproducibility (Marsella et al, 2011) and to non-invasively detect the presence of macroscopic myocardial fibrosis by the late gadolinium enhancement (LGE) technique ), demonstrated to be a significant prognosticator in all non ischaemic cardiomyopathies (Assomull et al, 2006; Bruder et al, 2010) and in TM (Pepe et al, 2017) .
Although considerable progress has been made in the knowledge, prevention and treatment of cardiac complications in TM patients, limited data are available in the literature regarding the relationship between heart complications in TM and gender. It has been repeatedly reported that female patients have a better prognosis than males, mainly due to a lower prevalence of cardiac disease in females (Borgna-Pignatti et al, 2004; Chouliaras et al, 2009; Telfer et al, 2009) .
Recently, a retrospective study involving 776 patients with TM showed that, compared to females, males had a significantly higher frequency of heart dysfunction and arrhythmias (Marsella et al, 2011) . However heart iron detected by T2* Magnetic Resonance Imaging (MRI) was comparable between the sexes, raising the hypothesis that women tolerate iron toxicity better, perhaps as an effect of reduced sensitivity to chronic oxidative stress (Proteggente et al, 2002) .
We assessed whether male gender was associated with a higher risk of cardiac iron accumulation and fibrosis, heart dysfunction and complications (heart failure, arrhythmias and pulmonary hypertension) in a large, multicentre cohort of TM patients in order to optimize the timing in cardiac follow-up.
Methods

Study population
We considered 1711 TM patients (822 males and 899 females, mean age 31Á09 AE 9Á08 years), consecutively enrolled in the Myocardial Iron Overload in Thalas saemia (MIOT) Network, an Italian cooperative registry formed by 66 haematological centres and 9 MRI sites where MRI examinations are performed using homogeneous, standardized and validated procedures (Meloni et al, 2009; Ramazzotti et al, 2009) . All the MIOT centres are linked by a central database (Meloni et al, 2009) , in which clinical and instrumental data are recorded from birth to the date of the first CMR scan.
The inclusion criteria of the MIOT project are: (1) male and female patients, all ages, with thalassaemias or sickle-cell disease, requiring a MRI to quantify cardiac and liver iron burden; (2) written informed consent; (3) written authorization for use and disclosure of protected health information. A patient is not eligible for inclusion if he/she has absolute contraindications to MRI.
All TM patients had been regularly transfused since early childhood and started undergoing chelation therapy from the mid-to-late 1970s, while patients born after the 1970s received chelation therapy from early childhood. MRI scanning was performed in the week immediately prior to scheduled blood transfusion.
All patients gave written informed consent. The study complied with the Declaration of Helsinki and was approved by the institutional ethics committee.
Images acquisition and analysis
MRI was performed on a 1Á5T scanner using an eight-element cardiac phased-array receiver surface coil and electrocardiogram (ECG)-gating.
MIO was assessed using a multi-slice multi-echo T2* approach. Three parallel short-axis views (basal, medium and apical) of the left ventricle (LV) were acquired at nine echo times (TEs) (Pepe et al, 2006a,b; Meloni et al, 2014) . Acquired images were analysed by expert CMR operators using a previously validated, custom-written software (Hippo-MIOT â ) (Positano et al, 2007) . The software provided the T2* value on each of 16 segments of the LV, according to the standard American Heart Association (AHA)/American College of Cardiology (ACC) model (Cerqueira et al, 2002) . The global heart T2* value was obtained by averaging all segmental T2* values. The inter-site, interstudy, intra-observer and inter-observer variability of the proposed methodology had been previously assessed (Pepe et al, 2006b; Ramazzotti et al, 2009 ). Steady-state free precession cines were acquired during 8-s breath holds in sequential 8-mm short axis slices from the atrioventricular ring to the apex to assess biventricular function parameters quantitatively in a standard way (Aquaro et al, 2016) using MASS â software (Medis, Leiden,
The Netherlands). The inter-centre variability for the quantification of cardiac function had been previously reported (Marsella et al, 2011) . Left and right atrial areas were measured from the 4-chamber view projection in ventricular end-systolic phase.
LGE short-axis images were acquired 10-18 min after Gadobutrol (Gadovist â ; Bayer; Berlin, Germany) intravenous administration at the standard dose of 0Á2 mmol/kg using a fast gradient-echo inversion recovery sequence. Also, vertical, horizontal and oblique long-axis views were acquired.
LGE was considered present when visualised in two different views .
LGE images were not acquired in patients with a glomerular filtration rate <30 ml/min/1Á73 m 2 and in patients who refused the contrast medium administration.
Diagnostic criteria and timing
A T2* measurement of 20 ms was taken as "conservative" normal value (Anderson et al, 2001; Positano et al, 2007) . LV and right ventricular (RV) dysfunction were diagnosed, respectively, in presence of a LV ejection fraction (EF) and a RVEF < 2 standard deviations (SD) from the mean values normalized to age and gender identified by CMR .
Heart failure (HF) was diagnosed by clinicians based on symptoms, signs and instrumental findings according to the AHA/ACC guidelines (Jessup et al, 2009 ). Arrhythmias were diagnosed if documented by ECG or 24-h Holter ECG if requiring specific medications. Arrhythmias were classified according to the AHA/ACC guidelines (Buxton et al, 2006) . Pulmonary hypertension (PH) was diagnosed if the trans-tricuspid velocity jet was greater than 3Á2 m/s (Cogliandro et al, 2008) . The term "cardiac complications" included HF, arrhythmias and PH.
If a patient developed more than one complication, only the first one that occurred was taken into account.
Given that all patients were followed-up from birth to the date of the first CMR scan, for all CMR outcomes (heart iron, ventricular dysfunction and myocardial fibrosis) the date of the scan corresponded to the end of the follow-up (duration of follow-up = age).
With regard to the cardiac complications, the study end date was the date of the onset of the disease. If no cardiac complication was developed, the follow-up ended in correspondence to the MRI.
Statistical analysis
All data were analysed using SPSS v.13.0 (Chicago, IL, USA) statistical package.
All continuous variables were expressed as the mean AE standard deviation (SD). Discrete variables were expressed as frequency and percentage.
The Cox proportional-hazard model was used to test the association between the considered prognostic variable (gender) and the outcomes. The results were presented as hazard ratio (HR) with 95% confidence intervals (CI). Kaplan-Meier curves were generated by relating the development of an outcome over time to each significant prognosticator. The log rank test was used to compare different strata in KaplanMeier analyses.
A 2-tailed probability value of 0Á05 was considered statistically significant. Table I shows the demographics and clinical characteristics at the time of the first CMR for all considered TM patients.
Results
Patients' characteristics
At the time of the first CMR scan, males were significantly younger than females (30Á49 AE 9Á02 years vs. 31Á65 AE 9Á11 years; P = 0Á008). Males were more frequently actual or former smokers (26Á0% vs. 15Á9%, P < 0Á0001). Figure 1 shows the chelation therapy of the patients at the time of the CMR and the compliance. Only the therapies received for longer than 6 months were considered. A significant difference between genders was detected in the frequency of the different regimens (P = 0Á001), as males were more frequently treated with Deferiprone (DFP) in monotherapy and females with combined Desferrioxamine (DFO) + DFP. The mean administered dosages of the chelators were: (1) DFP in combined regimen 67Á80 AE 18Á55 mg/kg body weight (bw)/ day at a frequency of 6Á32 AE 1Á29 days/week and DFO in combined regimen 40Á28 AE 8Á50 mg/kg bw/day at a frequency of 3Á87 AE 1Á44 days/week; (2) DFP as monotherapy 74Á53 AE 12Á33 mg/kg bw/day at a frequency of 6Á95 AE 0Á30 days/week. The dosage of DFP in the combined regimen was significantly lower than that used in monotherapy (P < 0Á0001). No difference in adherence to the chelation therapy was found between males and females (P = 0Á136).
Due to lack of collaboration, cardiac function was not assessed in 219 patients. The contrast medium was not administered in 511 patients. Table II shows the comparison between sexes in the development of cardiac iron overload, biventricular dysfunction and myocardial fibrosis. Compared to females, males had a risk almost double (HR = 1Á84) to develop cardiac dysfunction, although having a similar risk of accumulating iron in the heart.
Influence of gender on cardiac outcomes
When only patients with cardiac iron were considered, males maintained a significantly higher risk of developing cardiac dysfunction (HR = 1Á49, 95% CI = 1Á11-2Á02; P = 0Á009).
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Age at the MRI was comparable between patients without and with dysfunction (30Á89 AE 9Á11 years vs. 31Á47 AE 8Á55 years; P = 0Á432) as well as without and with cardiac iron overload (30Á80 AE 7Á23 years vs. 31Á19 AE 9Á51 years; P = 0Á088).
Mean age at the detection of ventricular dysfunction was 31Á37 AE 8Á25 years (range: 7-50 years) for males and 31Á62 AE 8Á99 years (range: 5-50 years) for females (P = 0Á533). Patients with dysfunction were more frequently actual or former smokers than patients without dysfunction (24Á8% vs. 19Á0%, P = 0Á025).
No association was detected between sex and myocardial fibrosis.
We recorded 262 (15Á3%) cardiac events: 165 episodes of HF, 104 arrhythmias (86 supraventricular, 11 ventricular and 7 atrioventricular blocks) and 14 PH. Mean age at the appearance of the first complication was 30Á34 AE 8Á35 years (range: 9-51 years) for the males and 30Á71 AE 8Á29 years (range: 14-50 years) for the females (P = 0Á657).
Overall, males showed a significantly higher risk of developing heart failure, arrhythmias and cardiac complications (Table II) . The different risk of arrhythmias was due to the supraventricular type (HR = 2Á69, 95% CI = 1Á72-422; P < 0Á0001). Figure 2 shows the Kaplan-Meier curves for those outcomes for which the male sex was a significant prognosticator. The log-rank test revealed a significant difference in all curves (male sex predicting cardiac dysfunction: P < 0Á0001; male sex predicting HF: P < 0Á0001; male sex predicting arrhythmias: P < 0Á0001; and male sex predicting cardiac complications: P < 0Á0001).
Gender, age, and cardiac outcomes
Looking at the Kaplan-Meier curves, it was noticed that, up to 20-30 years of follow-up, the curves for males and females were almost overlapping, whereas they clearly diverged after this time. Patients were therefore divided in to groups based on the follow-up duration: <10 years, between 10 and 20 years, 20-30 years, 30-40 years and ≥40 years. shows that a significant gender-specific difference in the frequency of ventricular dysfunction and cardiac complications appeared for patients followed for at least 20 years. Consequently, two subgroups of patients were identified: patients followed for less than 20 years and patients followed for more than 20 years. Table II shows the Cox regression for the two subgroups. In patients followed for less than 20 years, males and females had a comparable risk of developing cardiac iron overload, ventricular dysfunction, and cardiac complications. Conversely, if a follow-up longer than 20 years was considered, males exhibited a significantly higher risk of having ventricular dysfunction, heart failure, arrhythmias, and cardiac complications.
Discussion
This study evaluated the association of gender with cardiac iron and morbidity among patients with TM.
As previously shown in a cross-sectional study (Marsella et al, 2011) , we prospectively confirmed that males and females were at the same risk of accumulating iron in their hearts. Overall, up to 20 years of age the two sexes also had the same risk of developing ventricular dysfunction, heart failure, arrhythmias, and cardiac complications globally considered. When only patients aged at least 20 years were considered, a significant association was detected between male sex and ventricular dysfunction, heart failure, arrhythmias, and cardiac complications.
One possible hypothesis for this difference is the oxidative stress hypothesis (Marsella et al, 2011) . Oxygen radicals, produced as a consequence of metabolism, damage the cells and their machinery and, in presence of iron overload, they are particularly ubiquitous and dangerous. Oxidative stress plays an important role in the pathogenesis and perpetuation of arrhythmias (both ventricular and supraventricular) (Jeong et al, 2012) and of heart failure (Tsutsui et al, 2011) . A study comparing oxidative damage to DNA in males and females demonstrated significantly higher levels of modified DNA bases in males (Proteggente et al, 2002) . Females have a reduced sensitivity to chronic oxidative stress and, as a consequence, they tolerate iron toxicity better, especially in the long term (Kander et al, 2017) . The significantly lower risk of cardiac morbidity explains why females with TM survive longer than males with TM (Borgna-Pignatti et al, 2004) . The main limitation of our study is that we were not able to test the oxidative stress hypothesis, because we did not collect blood samples for testing oxidative stress.
Given that smoking status was associated with the presence of biventricular dysfunction and males were more frequently smokers, we cannot exclude that smoking may have also contributed to the highest risk of dysfunction detected in males.
Data was available regarding the chelation the patients were receiving at the time of the CMR; only those therapies received for longer than 6 months were considered, because significant changes in cardiac T2* can be seen after 6 months of chelation therapy. The males were more frequently treated with DFP and females with combined DFO + DFP. Besides, we had previously shown in a prospective observational study of the MIOT network that combined DFP+DFO and DFP monotherapy were equivalent in removing myocardial iron and improving heart function (Pepe et al, 2013) . In fact, a "mild" combination therapy with lower dosages of DFP and fewer days of DFO is generally used in clinical practice, so the significant lower frequency of dysfunction found in the female group does not seem to be due to the higher frequency of treatment with combined therapy.
According to National and International Guidelines (Cogliandro et al, 2008; Pennell et al, 2013) , thalassaemia major patients without cardiac involvement should undergo an annual ECG, echocardiography, 24-h ECG, and CMR. In the definition of this timing, the possible difference between males and females in the risk of development of cardiac diseases was not taken into account.
In this context, the present study may be a first step in redefining the timing of the cardiologic screening, based on patient gender. This is important because health care budgets around the world are being squeezed and optimized expenses represent a top priority for healthcare providers. Based on the results of the present study, we suggest the following timelines for TM patients: The first complete cardiac evaluation should be performed as soon as possible (Borgna-Pignatti et al, 2014; Casale et al, 2015) and all patients should have an annual cardiologic follow-up up to 20 years of age. Over 20 years of age, males should continue to receive an annual follow-up, whereas females, having an about 50% lower risk of cardiac diseases, could undergo complete cardiologic assessment every 2 years, in absence of pathological findings. Considering the costs of each diagnostic tool, our proposed approach could allow savings of €698Á35/year for each female patient. Of course, before our proposed timelines are applied globally, our findings should be confirmed by prospective multicentre trials conducted in other countries where the Mediterranean diet, which is high in antioxidants, is not adopted, and the mechanisms regarding the detected gender difference should be better defined.
It is important to underline that the role of liver iron and serum ferritin levels in assessing the CMR interval has not been taken into account because we had shown in a previous study that these parameters have lost their powerl in predicting cardiac complications in the widespread cardiac magnetic resonance era (Pepe et al, 2017) .
Conclusion
Females seem to tolerate iron toxicity better, possibly as an effect of reduced sensitivity to chronic oxidative stress (Kander et al, 2017) . Based on our data regarding the significantly different risk in developing cardiac complications, the followup may be performed every 24 months in females older than 20 years, thus optimizing health care costs.
